
Two More Pairs of Denosumab Biosimilars Enter US Market
The US biosimilar market recently saw the introduction of 2 pairs of denosumab biosimilars from Fresenius Kabi and Celltrion USA, significantly expanding treatment options for individuals living with bone-related conditions.1,2 Fresenius Kabi announced the …